Acetylcholinesterase inhibitors in Alzheimer's disease influence Zinc and Copper homeostasis

• Published in: Journal of trace elements in medicine and biology Vol. 55; pp. 58 - 63
• Main Authors: Giacconi, R., Giuli, C., Casoli, T., Balietti, M., Costarelli, L., Provinciali, M., Basso, A., Piacenza, F., Postacchini, D., Galeazzi, R., Fattoretti, P., Nisi, L., Fabbietti, P., Papa, R., Malavolta, M.
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-09-2019
• Subjects: Acetylcholinesterase - metabolism; Acetylcholinesterase inhibitors; Aged; Alzheimer Disease - blood; Alzheimer Disease - drug therapy; Alzheimer Disease - enzymology; Alzheimer Disease - metabolism; Alzheimer’s disease; Cholinesterase Inhibitors - administration & dosage; Cholinesterase Inhibitors - pharmacology; Copper; Copper - blood; Copper - metabolism; Female; Homeostasis - drug effects; Humans; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Linear Models; Male; Zinc - blood; Zinc - metabolism; Zinc homeostasis; Zip2; CRP; IL10; IADL; TNFα; AD; Alzheimer’s disease; IL1β; Acetylcholinesterase inhibitors; ADL; Inflammation; Aβ; Cu; IL6; MT2A; Zn; MMSE; NSAIDs; GDS; Zip3; AChEI; Zip2; Znt1; Copper; Zinc homeostasis
• ISSN: 0946-672X; 1878-3252
• DOI: 10.1016/j.jtemb.2019.06.001

[Display omitted]
Alzheimer's disease (AD) is the most common age-related neurodegenerative disease. An altered homeostasis of Zinc (Zn) and Copper (Cu), as well as a dysregulated expression of Zn-regulatory proteins have been previously described in AD. Acetylcholinesterase inhibitors (AChEI) are commonly used as AD treatment to improve cognitive function, but their effect on Zn homeostasis is still unexplored.
The aims of this study were to define the metal dyshomeostasis in AD patients, to investigate AChEI influence on Zn homeostasis and inflammation, and to analyze the relationship between cognitive impairment at two-year follow-up and metal concentrations, considering AChEI use.
84 Healthy Elderly (HE) and 95 AD patients were enrolled (62 AchEI user and 33 AchEI naïve). HE showed similar plasma Zn and Cu concentrations and Cu/Zn ratio in comparison to AChEI users, but significantly higher Zn level, as well as lower Cu amount and Cu/Zn ratio than AChEI naïve patients. Moreover, AChEI users had increased Zn plasma level, reduced Cu amount, Cu/Zn ratio, and IL1β concentration and lower Zip2 lymphocytic expression vs. naïve patients. A multiple linear regression analysis showed that the MMSE score decline after two-year follow-up was reduced by AChEI therapy and was positively associated with plasma Zn decrease over time.
Our data revealed that AChEI use may affect peripheral Zn and Cu homeostasis in AD patients, decrease Cu/Zn ratio demonstrating a general reduction of inflammatory status in patients under AChEI treatment. Finally, AChEI influence on circulating Zn could be implicated in the drug-related slowdown of cognitive decline.